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Abstract
Introduction: Commonly used free thyroxine (FT4) immunoassays can be falsely elevated due to interference causing misinterpreted thyroid func-
tion. We present two cases with high FT4 concentrations due to antibody interference. This study’s aim was to investigate the source of the FT4 
immunoassay interference and possibility of its removal by two different techniques in order to correct the discrepancy between obtained FT4 valu-
es and the patient’s clinical status.
Materials and methods: Two patients presented at their general practitioners’ with elevated FT4 concentrations in combination with a normal 
and increased thyroid stimulating hormone (TSH) concentrations. Clinical symptoms differed between patients but did not correspond with the 
hyperthyroid status suggested by the laboratory results. FT4 concentrations from both patients were measured on four common commercial immu-
noassays and the dialysis method before and after treatment with heterophilic blocking tubes and protein A/G. 
Results: Removal of interfering antibodies using protein A/G resulted in normal FT4 concentrations.
Conclusion: This report illustrates falsely elevated FT4 concentrations due to assay interference on the Immulite immunoassay analyser caused by 
heterophilic antibodies, which were eliminated by protein A/G treatment. We point out the importance of a close collaboration between doctors and 
the laboratory to avoid unnecessary clinical intervention.
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Case report
Introduction
In most patients euthyroidism, thyrotoxicosis or 
hypothyroidism is confirmed with the combina-
tion of free thyroxine (FT4) and thyroid stimulating 
hormone (TSH) measurements. Predominantly, 
thyroid function tests (TFT) are easily interpreted 
and correspond with the patient’s clinical status. 
However, in a limited number of cases the TFT and 
the clinical impression are discordant. A number of 
factors, including concurrent (non-thyroidal) ill-
ness, medication (e.g. amiodarone, thyroxine) and 
immunoassay interference, can cause these dis-
crepancies (1-3). These factors should be excluded 
in order to prevent unnecessary diagnostic and 
therapeutic interventions (4).
Currently, the competitive immunoassay is a com-
mon method to determine FT4 concentrations in 
diagnostic laboratories. These assays measure the 
unbound thyroxine fraction whereby the vast ex-
cess is protein-bound (> 99.5%). Immunoassay in-
terference can cause false (positive or negative) 
FT4 results that can lead to misdiagnosis and po-
tentially harmful therapy (5).
Here we describe two patients with a discrepancy 
between the TFT and the patient’s clinical status. 
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The aim of the study was to investigate the source 
and possible removal of the FT4 immunoassay in-
terference in these two patients.
Material and methods
Case reports
Patient one 
A 58-year-old woman presented with fatigue and 
weight gain at the general practitioner (GP). 14 
years earlier, she was diagnosed with Hashimoto’s 
autoimmune thyroiditis and has been using levo-
thyroxine since. She was evaluated and thyroid 
function test revealed a markedly elevated FT4 (28 
pmol/L; reference range 11–21 pmol/L) with nor-
mal TSH (1.5 mU/L; reference range 0.16–4.6 mU/L). 
Two months later, upon return to the GP, levothy-
roxine dosage was decreased since she com-
plained about palpations in combination with a 
still markedly increased FT4 (31 pmol/L) and nor-
mal TSH (1.1 mU/L). The GP clinically questioned 
her hyperthyroid status since she also complained 
about fatigue and weight gain, not in line with hy-
perthyroidism. Despite lowering her levothyroxine 
dosage, FT4 measurements kept increasing further 
now in combination with an increased TSH of 5.8 
mU/L, after which she was referred to a medical 
specialist who in collaboration with the clinical 
chemist suspected an interference on the FT4 as-
say as the culprit (Table 1).
Patient two
A 65-year-old male presented with abdominal 
pain, no change in defecation pattern or weight at 
the GP. He was using levothyroxine for 10 years af-
ter being diagnosed with hypothyroidism. Upon 
evaluation, his thyroid function tests revealed an 
increased FT4 (36 pmol/L) and TSH (7.9 mU/L). The 
GP contacted the endocrinologist and discussed 
the clinical symptoms in combination with the lab-
oratory results. They concluded that either there 
was a problem with the patient’s medication com-
pliance or a laboratory discrepancy with the TFT. 
Upon return to the GP two months later patient’s 
medication compliance was questioned but found 
adequate and laboratory was repeated with an in-
creased FT4 (29 pmol/L) and TSH (11.5 mU/L). The 
GP contacted the clinical chemist since the clini-
cal status of the patient did not match the TFT 
and interference on the FT4 assay was discovered 
by repeating the analysis on a different platform 
(Table 1).
Interference testing
Sera from the patients described were used in this 
study. Blood was collected in 10 mL serum vacu-
um tubes with silica clot activator and polymer gel 
separator: BD SST II Advance Tube (Becton, Dickin-
son and Company, Franklin Lakes, NJ, USA). Sera 
were obtained with informed consent from the 
patients following national and institutional guide-
lines.
In addition, commercial sera from two patients 
with a human anti-mouse antibodies (HAMA) con-
centration of 2464 ng/mL and a rheumatoid factor 
(RF) concentration of 440 IU/mL were included as 
known interfering factors for immunoassays 
(product number 3PH490, lot number SD3158-56 
and product number 3PH330, lot number SD3142-
31, respectively, from Scantibodies Laboratory, 
Santee, USA) (4).
Patient Assay Immulite Immulite reference range Cobas
Cobas 
reference range DXi
DXi
reference range
Patient 1
FT4, pmol/L 42 11–21 - - 14 9–25
TSH, mU/L 0.76 0.16–4.60 - - 0.69 0.16–4.60
Patient 2
FT4, pmol/L 26 11–21 15 10–21 11 9–25
TSH, mU/L 6.40 0.16–4.60 7 0.40–4.00 6.4 0.16–4.60
 FT4 – free thyroxine.  TSH – thyroid stimulating hormone.
Table 1. Initial levels of TSH and FT4 obtained in patients by respectively Immulite, Cobas and DXi platforms
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FT4 measurements were performed on four differ-
ent immunoassay analyzers: Cobas Modular E 
(Roche Diagnostics, Basel, Switzerland), Immulite 
2500 (Siemens, Munich, Germany), DXi (Beckman 
Coulter, Krefeld, Germany) and Vitros ECi (Ortho 
Clinical Diagnostics, Johnson & Johnson, Beerse, 
Belgium) and compared to the equilibrium dialysis 
as described by Docter et al. (7). The reference 
ranges for FT4 were as follows: for Cobas Modular 
12–22 pmol/L, for Immulite 2500 12–23 pmol/L, for 
DXi 8–14 pmol/L and for Vitros 11–25 pmol/L. The 
FT4 reference range for the Dialysis method was 
determined in-house (14–29 pmol/L). FT4 meas-
urements were normalized by dividing the results 
with the upper limit of normal (ULN) for each assay 
(FT4/ULN). Figure 1 schematically presents FT4 
Figure 1. Schematic presentation of the FT4 measurement commonly used in routine clinical chemistry laboratories. 
(A) one-step labelled T4 analog (Immulite, Siemens) in which the patients serum is simultaneously incubated with the labelled T4 an-
alog and competes for binding with the immobilized anti-T4 antibody. After incubation, the unbound fraction is removed by wash-
ing and the signal recorded. 
(B) The one-step analog two-step incubation (Cobas, Roche Diagnostics) uses a labelled T4 antibody in the first incubation round, 
followed by a second incubation step in which the T4 analog is added. Only the T4 analog, with or without the labelled T4 antibody, 
will subsequently bind via biotin and streptavidin and become immobilized. The unbound fraction is removed by washing and the 
signal is recorded. 
(C) The two-step labelled T4 analog method (DXi, Beckman Coulter) introduces the T4 antibody in the first incubation round to the 
patient’s serum. During this incubation step, the T4 antibody becomes immobilized to the solid phase followed by a wash step. In the 
second incubation step, the labelled T4 analog is allowed to bind to the vacant anti-T4 antibody binding sites, the unbound labelled 
T4 analog is washed away and the signal recorded.
(D) The one-step labelled antibody method (Vitros, Ortho Clinical Diagnostics) incubates the patient’s serum with immobilized T4 
analog and uses a labelled anti-T4 antibody. The FT4 in the serum competes for binding with the T4 analog followed by a wash step 
and signal generation. 
In all these designs, the signal generated is inversely proportional to the FT4 concentration. 
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measurements on each immunoassay analyzer 
commonly used in routine clinical chemistry labo-
ratories. FT4 measurements on Cobas Modular E, 
Immulite 2500, and DXi were performed in dupli-
cate, whereas FT4 measurements on Vitros ECi and 
equilibrium dialysis was done in singlicate. For the 
duplicate FT4 measurements, intra-assay variation 
was determined by taking the 95% confidence in-
terval of the standard error based on the differ-
ence between these measurements. 
Treatment of serum with heterophilic blocking 
tubes (HBT) (Scantibodies Laboratory, Santee, 
USA) was performed according to manufacturer’s 
instructions. The recombinant fusion protein that 
combines immunoglobulin (Ig) G binding domains 
of both Protein A and Protein G (protein A/G) aga-
rose beads; Pierce Protein A/G Plus Agarose (Ther-
mo Scientific, Rockford, USA) were washed and in-
cubated at 4 °C overnight with sera. The effect of 
HBT and protein A/G treatment on IgG and IgM 
concentrations of the sera was measured using Im-
mulite 2500. Antibodies against thyroglobulin (TG) 
were determined by a sandwich immunoassay 
(ImmunoCap 250, Phadia Thermoscientific, Upp-
sala, Sweden). Presence of thyroid hormone auto-
antibodies (THAA) were tested with agar gel elec-
trophoresis (8). 
Results
The initial patient FT4 and TSH values were ob-
tained using the Immulite analyzer; subsequently, 
FT4 and TSH were measured on DXi or DXi and Co-
bas for patient 1 and 2, respectively. Based on the 
obtained FT4 concentrations, as presented in Ta-
ble 1, assay interference was suspected. As inter-
ference due to antibody presence was suspected 
and antibody removal was performed. 
Antibody removal
To establish a baseline before removal of the anti-
bodies, we measured IgM and IgG in the patient 
sera in duplicate. IgM (patient 1 = 1.19 g/L and pa-
tient 2 = 0.95 g/L) and IgG (patient 1 = 12.8 g/L and 
patient 2 = 9.9 g/L) were within the reference 
range of 0.45–2.30 g/L for IgM and 7.0–15.5 g/L for 
IgG. After either Protein A/G or HBT treatment, IgM 
and IgG were measured again in duplicate to in-
vestigate the effectiveness of antibody removal. 
Analysis of all sera showed a 40% decrease of IgM 
concentrations upon HBT treatment whereas no 
significant effect on the IgG concentrations was 
detected (Figure 2). Only a quarter of the original 
IgM concentrations could be detected after pro-
tein A/G treatment whereas almost no IgG con-
centrations were detected (Figure 2).
Subsequent analysis of the patient sera showed el-
evated FT4 with the Immulite assay in comparison 
with the DXi, Cobas, Vitros and Dialysis method for 
patient 1 and 2 (Figure 3 A and B). No interference 
of HAMA (2464 ng/mL) or RF (440 IU/mL) was de-
tected in the FT4 assay performed on 4 different 
analyzers or using the dialysis method (Figure 3 C 
and D). Removal of antibodies with protein A/G 
treatment resulted in lower FT4 concentrations for 
the Immulite and Cobas assays for sera 1 and 2, 
whereas no effect or a slight increase was seen in 
DxI, Vitros and Dialysis methods for these sera. FT4 
results after treatment with HBT gave similar re-
sults as untreated sera (Figure 3). 
TSH, total triiodothyronine and total thyroxine 
showed no aberrant results on the 3 different ana-
lyzers, indicating that interfering antibodies do 
not necessarily give aberrant results on the whole 
thyroid panel used in current hospital laboratories.
In order to determine the source of the interfering 
antibody, anti-thyreoglobuline (anti-TG) and THAA 
were measured in sera 1 and 2. Both samples con-
tained high concentrations of anti-TG (388 U/mL 
Figure 2. Measurement of IgM and IgG in patients’ sera and 
commercial serum with HAMA or RF. Results obtained by un-
treated sera are shown with black bars, sera treated by HBT 
with grey bars and sera treated by protein A/G with white bars. 
Error bars represent standard deviation of the mean.
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and 66 U/mL for patient 1 and 2, respectively, with 
a reference value < 40 U/mL) but did not contain 
THAA. Therefore we speculated anti-TG might in-
terfere with the Immulite assay in particular. How-
ever a random selection of 26 sera with high titers 
of anti-TG showed no discordance between Immu-
lite and Roche FT4 results (data not shown).
Clinical follow-up
After detection of FT4 assay interference in the 
first patient, levothyroxine therapy was increased 
to her regular dosage. Upon re-evaluation 3 
months later she presented with normal TSH (0.81 
mU/L), normal FT4 (13 pmol/L) and clinically euthy-
roid. In the second patient the interference was 
discovered in an earlier stage. Upon re-evaluation 
he presented with normal TSH (2.5 mU/L) and clin-
ically euthyroid. For patients FT4 concentrations 
were no longer monitored using the Immulite 
method because of the interference.
Discussion
In this report we performed a side-by-side com-
parison of the efficacy of two interfering antibody 
removal techniques in FT4 assays across multiple 
immunoassay analyzers. We show that protein A/G 
treatment prior to analysis performed superiorly in 
comparison with the commonly used HBT treat-
ment to remove interfering antibodies. Our data 
demonstrates its effectiveness for the first time by 
IgM and IgG measurement before and after pro-
tein A/G treatment.
This study showed that in the Immulite immuno-
assay discrepant FT4 results in two patients were 
due to interfering antibodies. Several interferenc-
Figure 3. Measurements of FT4 by four different analyzers and the dialysis method of patient 1 (A), patient 2 (B), commercial serum 
with HAMA (C) and commercial serum with RF (D). Results obtained by untreated sera are shown with black bars, sera treated by HBT 
with grey bars and sera treated by protein A/G with white bars. Error bars represent intra-assay variation.
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es of the FT4 assay have been described including 
heterophilic antibodies (4), human anti mouse an-
tibodies (HAMA) (4), thyroid hormone auto-anti-
bodies (THAA), albumin variants (familial dysalbu-
minaemic hyperthyroxinaemia) and heparin use 
(9-14). Since patients did not use heparin it was 
postulated that an antibody caused the grossly el-
evated FT4 results on the Immulite 2500 in com-
parison with other analyzers and equilibrium dial-
ysis. Several different immunoassay tests have 
been reported to give aberrant results when inter-
fering antibodies are present (15-18). Antibody in-
terference was eliminated by treatment with pro-
tein A/G sepharose but not with HBT. Furthermore, 
we have demonstrated that protein A/G treatment 
has little effect on FT4 immunoassay measure-
ment.
When FT4 immunoassay interference is suspected, 
retesting with a different commercial assay is a 
useful strategy (18,19). However, comparison of 
FT4 results between different methods can be 
challenging (20,21). One should be aware of these 
differences between laboratory methods and use 
the appropriate reference intervals when inter-
preting results. 
Different strategies have been reported for remov-
al of interfering antibodies (1,4,10,22). Upon treat-
ment of the sera we were able to partially remove 
IgM antibodies with HBT treatment whereas Pro-
tein A/G removes both IgM partially and IgG com-
pletely. The latter treatment led to normal FT4 
concentrations on the Immulite assay comparable 
to concentrations found using DXi, Cobas, Vitros 
and dialysis methods. We chose to treat with pro-
tein A/G instead of polyethylene glycol precipita-
tion (PEG) because of the specific ability of protein 
A/G to bind and remove only immunoglobulins. 
Known disadvantages for PEG treatment are the 
non-specific nature causing precipitation of pro-
teins and ability to interfere with immunoassays 
(23). Since the protein A/G treatment corrected the 
FT4 results on the Immulite assay, we speculated 
THAA might be the culprit. THAA have been re-
ported to be of the IgG class, which is almost com-
pletely removed by protein A/G treatment (24). 
However no THAA were detected in our sera. Since 
THAA coexists with antibodies to thyroglobulin, 
we screened an additional 26 sera on Immulite 
and Cobas but no discrepancies were found. We 
speculate that an antibody interferes with the Im-
mulite assay since partial IgM and near complete 
IgG antibodies removal corrected the high results 
on the Immulite assay. Since none of the other as-
says are influenced by this antibody we postulate 
two possible hypotheses why the Immulite assay 
(one-step method) produced aberrant high FT4 re-
sults. Firstly, the interfering antibodies interacts 
with the capture antibodies and somehow pre-
vents tracer, but not FT4 binding. Antibodies in the 
remaining assays differ and therefore do not inter-
act with the interfering substance. The exact bind-
ing properties of the antibodies used are proprie-
tary information and therefore could not be com-
pared to possibly identify the source of interfer-
ence. Secondly, the interfering antibody binds the 
tracer directly and prevents the tracer from bind-
ing to the capture antibody. Therefore, interfering 
antibody-tracer complex is washed away resulting 
in falsely elevated FT4 result (competitive immu-
noassay). This is only possible in a one-step assay 
since the interfering substance remains present 
during the entire procedure. The other one-step 
immunoassay, Cobas Modular E, has two consecu-
tive incubations. Firstly, serum and capture anti-
body are incubated followed by a second incuba-
tion whereby tracer is added. The test is complet-
ed by a wash step. This assay is possibly also af-
fected by the interfering antibody whereby pro-
tein A/G treatment reduces FT4 concentrations. 
The DXi method is a two-step assay with a sepa-
rate washing step that potentially removes the in-
terfering substance before analysis (Figure 1) and 
consequently avoiding direct contact with the 
tracer. The Vitros method uses a one-step princi-
ple like the Immulite assay but interference is seen 
only with the Immulite. Our hypothesis is that the 
antibody that interferes in the Immulite and Cobas 
assays is somehow blocked by the blocking agents 
used in the Vitros assay or the labeled anti-T4 anti-
body is modified in such a way that it is less likely 
to cause aberrant results by antibodies present in 
human serum. Since the dialysis method is inde-
pendent of binding proteins and no antibodies are 
used the interfering immunoglobulin will not alter 
the results of the dialysis FT4 measurement.
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HBT treatment might be an effective procedure in 
routine laboratories in case immunoassays results 
are suspected to be influenced by interfering anti-
bodies (25,26). However, most commercial immu-
noassays already use blocking agents. This possi-
bly explains the fact no differences were observed 
in HBT treated and untreated HAMA serum (Figure 
2C).
Looking for the source of the interference we in-
cluded sera that contained HAMA and RF antibod-
ies. These have been reported to interfere with 
hormone assays (1) but in our study we did not 
find any effect on the FT4 measurements on the 
Immulite Modular, DXi, Vitros analyzers or the dial-
ysis method. 
In conclusion the interfering antibody in this study 
is only able to disturb the FT4 results in the Immu-
lite assay. By comparing FT4 result of different 
commercial immunoassays interference was con-
firmed. HBT were not able to remove the interfer-
ing substance judging by the FT4 levels above the 
reference levels after treatment in the Immulite as-
say. After protein A/G treatment the FT4 results 
dropped to levels within reference, comparable to 
those measured with the other methods. Leading 
to the conclusion that protein A/G treatment ef-
fectively removes the interfering antibody. In addi-
tion this study shows the importance of proper 
collaboration between a doctor and clinical chem-
ist when laboratory results are not in line with the 
clinical presentation.
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